A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is a comparison between MK0787B and standard therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Amikacin; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Piperacillin, Tazobactam Drug Combination; Vancomycin

Criteria

Inclusion Criteria:

• Greater than 18 years of age

• Patient is diagnosed with nosocomial pneumonia

Exclusion Criteria:

• Immunological deficient patients

• Pregnant women and nursing mothers

• A fungus is identified before the study enrollment

• Received vancomycin or imipenem for more than 5 days before icu admission